Changes in neovascular activity following fixed dosing with an anti-vascular endothelial growth factor agent over 52 weeks in the phase III VIEW 1 and VIEW 2 studies.
Darius M MoshfeghiDesmond ThompsonNamrata SarojPublished in: The British journal of ophthalmology (2019)
In this post hoc analysis, fixed dosing with an anti-VEGF agent over 52 weeks eliminated disease activity (absence of both leakage and fluid) in most eyes. The effect of anti-VEGF treatment on leakage/fluid status favoured PC versus occult lesions.
Keyphrases
- vascular endothelial growth factor
- disease activity
- phase iii
- rheumatoid arthritis
- systemic lupus erythematosus
- endothelial cells
- rheumatoid arthritis patients
- open label
- ankylosing spondylitis
- clinical trial
- gestational age
- juvenile idiopathic arthritis
- optical coherence tomography
- phase ii
- double blind
- placebo controlled
- case control
- smoking cessation